research group.
This specific role is will drive the development and application of technologies to enrich for and map DNA damage and modifications within the human genome. You will explore how that damage is processed leading to repair, mutagenesis or damage tolerance. Within the IGC you will be co-supervised by biochemist Dr Tom Deegan.
The successful candidate will have experience in molecular biology and nucleic acid manipulation along with core biochemistry techniques including protein purification. You will have ownership of your own projects and work closely with experts in the analysis of high-throughput sequencing and mass-spectrometry data, familiarity with such platforms would be an advantage.
The post holder will have many opportunities for multidisciplinary collaborative working both within the IGC and with CAUSE partners based at the Sanger Institute, Hubrecht Institute, Harvard University, University of San Diego and University of Minnesota. The wider Cancer Grand Challenge community will also provide excellent opportunities for training, professional and network development.
Applicants must have a PhD in molecular biology, biochemistry or a related discipline for appointment at Research Associate level. Applicants close to completion of their PhDs will also be considered where experience is directly relevant. Please see the job description and person specification document associated with this advert for the full list of criteria.
This post is full-time (35 hours per week); however, we are open to considering part-time or flexible working patterns. Initially a 24-month contract is offered, with the possibility of extension.
£41,064 to £48,822 per annum pro-rata if part-time: Grade UE07
